IP Library Granted Patent US 8,748,375
Granted Patent B2
US 8,748,375 · App. 13/256,779 · Granted Jun 10, 2014

Methods for affecting body composition using amylin agonists

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,748,375
App. No.
13/256,779
Granted
Jun 10, 2014
Kind
B2
Abstract

Methods for affecting body composition include the use of amylin agonists, such as pramlintide or davalintide. Total body weight may be reduced, maintained or even increased; however, the body fat is reduced or body fat gain is prevented, while lean body mass is maintained or increased.

Claims (4)

1. A method for reducing body fat or body fat gain in a subject in need of treatment while maintaining or increasing lean body mass; of altering a body composition of a subject in need of treatment, wherein body fat is reduced and lean body mass is maintained or increased; for reducing body weight in a subject in need of, or desirous of, weight reduction; or

for reducing caloric intake in a subject in need of reduction thereof, the method comprising administering an effective amount to the subject an amylin agonist, wherein the amylin agonist comprises the sequence set forth in SEQ ID NO:138, thereby reducing body fat or body fat gain while maintaining or increasing lean body mass; altering a body composition while reducing body fat and maintaining or increasing lean body mass; reducing body weight; or reducing caloric intake, wherein the amylin agonist is administered in a manner sufficient to maintain an average plasma concentration of the amylin agonist of at least about 50 pg/mL for a period of time selected from the group consisting of at least about 1 hr, at least about 2 hrs, at least about 3 hrs, at least about 4 hrs, at least about 5 hrs, at least about 6 hrs, at least about 7 hrs, at least about 8 hrs, at least about 12 hrs, at least about 1 day, at least about 2 days, at least about 3 days, at least about 1 week, at least about 2 weeks, and at least about 1 month.

2. The method of claim 1 , wherein the amylin agonist is administered parenterally.

3. The method of claim 1 , wherein the amylin agonist is davalintide.

Assignments (3)
AMYLIN PHARMACEUTICALS, LLC ASSIGNS AN EQUAL AND UNDIVIDED ONE-HALF OF ITS ENTIRE RIGHT, TITLE AND INTEREST TO ASTRAZENECA PHARMACEUTICALS LP Recorded Oct 26, 2012
From: AMYLIN PHARMACEUTICALS, LLC
To: ASTRAZENECA PHARMACEUTICALS LP
Reel/Frame 029195/0555 →
CHANGE OF NAME Recorded Oct 25, 2012
From: AMYLIN PHARMACEUTICALS, INC.
To: AMYLIN PHARMACEUTICALS, LLC
Reel/Frame 029198/0396 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 7, 2011
From: MACK, CHRISTINE M.; ROTH, JONATHAN DAVID
To: AMYLIN PHARMACEUTICALS, INC.
Reel/Frame 027031/0061 →